These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27904766)

  • 1. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
    Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
    Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
    Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
    Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.
    Wu W; Lu P; Patel P; Ma J; Cai KQ; Mallikarjuna VS; Poureghbali S; Nakhoda SR; Nejati R; Lynn Wang Y
    Oncogene; 2023 Feb; 42(6):409-420. PubMed ID: 36482202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
    Jain N; Singh S; Laliotis G; Hart A; Muhowski E; Kupcova K; Chrbolkova T; Khashab T; Chowdhury SM; Sircar A; Shirazi F; Singh RK; Alinari L; Zhu J; Havranek O; Tsichlis P; Woyach J; Baiocchi R; Samaniego F; Sehgal L
    Blood Adv; 2020 Sep; 4(18):4382-4392. PubMed ID: 32926124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-
    Yoon SB; Hong H; Lim HJ; Choi JH; Choi YP; Seo SW; Lee HW; Chae CH; Park WK; Kim HY; Jeong D; De TQ; Myung CS; Cho H
    Acta Pharm Sin B; 2023 Mar; 13(3):1093-1109. PubMed ID: 36970199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell receptor signaling in diffuse large B-cell lymphoma.
    Young RM; Shaffer AL; Phelan JD; Staudt LM
    Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
    Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).
    Kim PM; Nejati R; Lu P; Thakkar D; Mackrides N; Dupoux V; Nakhoda S; Baldwin DA; Pei J; Dave SS; Wang YL; Wasik MA
    Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37730436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.
    Zheng X; Ding N; Song Y; Feng L; Zhu J
    Cancer Cell Int; 2014 Apr; 14(1):32. PubMed ID: 24693884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
    Kozaki R; Vogler M; Walter HS; Jayne S; Dinsdale D; Siebert R; Dyer MJS; Yoshizawa T
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma.
    Wang S; Clapper E; Tonissen KF; Di Trapani G
    Antioxidants (Basel); 2023 Feb; 12(2):. PubMed ID: 36830087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
    Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
    Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.